PMN (ProMIS Neurosciences) Moat Score: 3/10 (As of Jul. 01, 2026)


PMN ProMIS Neurosciences Inc PMN
30 GF Score
Price $13.39
! 2 Warning Signs
View Full Analysis

What is ProMIS Neurosciences Moat Score?

ProMIS Neurosciences PMN +22.42% 30 Moat Score is 3 as of Jul. 01, 2026. GuruFocus rates PMN with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,401 Biotechnology companies, ProMIS Neurosciences ranks better than 75.52% on this metric.

ProMIS Neurosciences has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

ProMIS Neurosciences has No Moat: ProMIS Neurosciences Inc has weak competitive advantages. While it may possess some valuable intellectual property in the biotech sector, it lacks market leadership, brand strength, and significant regulatory barriers. The company's success is highly dependent on R&D outcomes and regulatory approvals.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes ProMIS Neurosciences might have No Moat - Very weak/transient advantages.

ProMIS Neurosciences  (NAS:PMN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

ProMIS Neurosciences Moat Score Related Terms

PMN vs BMEA, ANIX, ATRA: Moat Score Comparison

For the Biotechnology subindustry, ProMIS Neurosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProMIS Neurosciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's Moat Score falls into.


PMN
30GF Score
ProMIS Neurosciences Inc PMN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
ProMIS Neurosciences (PMN) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, ProMIS Neurosciences ranks #343 out of 1401 companies in the Biotechnology industry, placing it in the top 24.5%.
Is ProMIS Neurosciences' Moat Score too high?
ProMIS Neurosciences' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. ProMIS Neurosciences' value of 3 is 50% above this industry median. Based on the distribution chart, ProMIS Neurosciences ranks #343 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ProMIS Neurosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' Moat Score compare to BMEA and ANIX?
According to the Biotechnology industry distribution chart, ProMIS Neurosciences ranks #343 out of 1401 companies for Moat Score. This places ProMIS Neurosciences in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. ProMIS Neurosciences' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProMIS Neurosciences's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProMIS Neurosciences's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. ProMIS Neurosciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProMIS Neurosciences Business Description

Other Exchanges 23J:Germany
Address 1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
30GF Score

Get the complete analysis for PMN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.39
Price